Baxter Shares Tank As 2026 Profit Guidance Falls Below Expectations
Feb 12, 2026, 1:31 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Historical earnings misses frequently lead to declines in stock prices as investor confidence wanes. For instance, underperformance in key reporting periods historically results in corrections in the healthcare sector, similar to Baxter's current situation.
AI summary
What happened, with direct paths to the underlying reporting
Baxter's fourth-quarter adjusted EPS of 44 cents was below both management's guidance and Wall Street estimates, primarily due to an unfavorable product mix. This earnings miss could raise concerns among investors about operational efficiency and future growth prospects, potentially impacting share performance negatively in the near term.
Baxter's Q4 EPS of 44 cents missed forecasts and guidance.
The EPS shortfall was caused by an unfavorable product mix.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Baxter beat Q2 expectations with adjusted EPS of 0.54 and revenue of $2.96 billion, driven by Medical Products growth and tariff refunds. The company raised full-year 2026 guidanc…
Baxter International raised its full-year profit forecast after reporting a quarterly beat, led by strong demand for IV solutions and other medical products. The results underscor…
Baxter's first-quarter results exceeded Wall Street expectations, primarily due to strong sales in its medical products and therapies unit. This performance may indicate continued…
Baxter International is dealing with significant shortages of its cancer drugs containing ifosfamide, according to the EU medicines regulator. These shortages are expected to cont…